

# Effect of novel plant antioxidant from *Aronia melanocarpa* on cardiovascular risk factors in patients after MI

Marek A. Naruszewicz  
Medical University of Warsaw



Akademia Medyczna  
w Warszawie

# Proposed mechanism by which flavonoids may reduce risk for cardiovascular diseases

## ➤ Oxidative stress

- ✓ Scavenge reactive oxygen and nitrogen species
- ✓ Chelate redox-active transition metal ions
- ✓ Spare and interact with other antioxidants
- ✓ Inhibition of the redox-sensitive transcription factors
- ✓ Inhibition of pro-oxidant enzymes
- ✓ Induction of antioxidant enzymes

# Proposed mechanism by which flavonoids may reduce risk for cardiovascular diseases


- **Growth of atherosclerotic plaque**
  - Reduce adhesion molecule expression
  - Anti-inflammatory
  - Reduce the capacity of macrophages to oxidatively modified LDL



# Proposed mechanism by which flavonoids may reduce risk for cardiovascular diseases

- Platelet function and haemostasis
  - Inhibit platelet aggregation
- Blood pressure and vascular reactivity
  - Promote nitric oxide-induced endothelial relaxation

# The role of CD36 and LOX-1 receptors in foam cell development







# Aronia Berries

- Aronia (*Photinia melanocarpa*, also known as *Aronia melanocarpa* and *Aronia nigra*), is a native American bush that has been successfully exported to Eastern Europe and is commercially grown in Denmark, Poland, Russia and elsewhere.
- Known commonly as "chokeberry" or "blak chokeberry", (*Photinia melanocarpa*) has at least two cousins worth mentioning. These are *Photinia floribunda*, also known as *Aronia atropurpurea*, the "purple chokeberry", and *Photinia pyrofilia*, also known as *Aronia arbutifolia*, the "red chokeberry". The former ranges from Mississippi to Wisconsin, Georgia into Canada, and all areas in between. The latter ranges from Texas-Oklahoma eastward through Tennessee to the Atlantic and from Florida northward into Canada. The Aronia berry has all of the healthy attributes of the cranberry, but also contains five to ten times the amount of anthocyanins and polyphenols of a cranberry.



# Antioxidant activity (ORAC), Anthocyanin Content and Phenolic Content in Fruit of Blueberry, Cranberry, Lingonberry and Chokeberry

species	ORAC ( $\mu\text{mol}$ of TE/g)	Anthocyanin (mg/g)	Total phenolic (mg/g)
Blueberry	28.9	1.20	4.12
Cranberry	18.5	0.32	3.15
Lingonberry	38.1	0.45	6.52
<b>Chokeberry</b>	<b>160.2</b>	<b>4.28</b>	<b>25.56</b>

W. Zheng, S.Y. Wang "Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries and lingonberries", J.Agric.Food Chem. 51, (2003) 501-509




# Effect of *A. melanocarpa* extract on superoxide production by human arterial wall cells from patients with cardiovascular risk factors




Data are shown as means +/-SEM, \* -  $p < 0,05$  vs. native using appropriate tests depending on data distribution

# Effect of *A. melanocarpa* extract on vasoconstriction


Increasing concentration of  
*A. melanocarpa* extract



Increasing concentration of  
*A. melanocarpa* extract




# Correlation between endothelium function and vasorelaxation activity of *A. melanocarpa* extract






# Mechanism of vasorelaxation activity of *A. melanocarpa* polyphenols

## Endothelium function




## Role of eNOS (incubation with L-NAME)





# Superoxide production in platelets and effect of *A. melanocarpa* polyphenols

Production of  $O_2^{\cdot -}$  in platelets  
- correlation with risk factors




# Superoxide production in platelets and effect of *A. melanocarpa* polyphenols






# Effect of increasing *A. melanocarpa* polyphenols concentrations on platelet aggregation


Control




Risk factors



# The effect of increasing concentrations of Aronia flavonoids from chokeberry on eNOS expression in HUVEC cells



# The effect of increasing concentrations of Aronia flavonoids from chokeberry on LOX-1 expression in HUVEC cells





# Product: Aronia fruits extract /ARONOX/ Scientific name: Aronia meelanocarpa (chokeberry)

Parameter	Result
Appearance	Powder
Colour	Red-brown
Humidity	max 8%
Anthocyanins Cy-3-O-Ga	20-25%
Polimeric procyanidins (+)(-) epicatechin	>55%
Phenolic acids	9%
Antioxidant activity ( $\mu$ M Trolox/g dried weight)	
DPPH radicals	118.7
ABTS radicals	106.1



ELSEVIER

*Atherosclerosis* 194 (2007) e179–e184

---

---

ATHEROSCLEROSIS

---

---

[www.elsevier.com/locate/atherosclerosis](http://www.elsevier.com/locate/atherosclerosis)

## Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI)

Marek Naruszewicz<sup>a,c,\*</sup>, Iwona Łaniewska<sup>b</sup>, Barbara Millo<sup>c</sup>, Mirosław Dłużniewski<sup>b</sup>

<sup>a</sup> *Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Ul. Banacha 1, Warszawa, Poland*

<sup>b</sup> *II Cardiology Clinic, The Medical University of Warsaw, Poland*

<sup>c</sup> *Center for Atherosclerosis Research, Pomeranian Medical University Szczecin, Poland*

Received 6 October 2006; received in revised form 6 December 2006; accepted 21 December 2006

Available online 21 February 2007

# Methods

- This was a double-blind, placebo-controlled, parallel trial. Forty-four patients (11 women and 33 men, mean age 66 years) who survived myocardial infarction and have received statin therapy for at least 6 months (80% dose of 40 mg/day simvastatin) were included in the study. The subjects were randomised to receive either 3 x 85 mg/day of chokeberry flavonoid extract or placebo for a period of 6 weeks.




# Clinical and Demographic Characteristics of MI Patients

	Aronia flavonoids (n=22)	Placebo (n=22)
<b>Age</b>	<b>65.87 ± 8.3</b>	<b>66.1 ± 7.9</b>
<b>Sex (women, men)</b>	<b>6/16</b>	<b>5/17</b>
<b>BMI (kg/m<sup>2</sup>)</b>	<b>26.5 ± 3.5</b>	<b>26.9 ± 2.5</b>
<b>MI (years after)</b>	<b>5.2 ± 2.0</b>	<b>5.4 ± 2.1</b>
<b>Diabetes (%)</b>	<b>19</b>	<b>23</b>
<b>Hypertension (%)</b>	<b>32</b>	<b>36</b>
<b>Current smokers (%)</b>	<b>14</b>	<b>19</b>
<b>Medication</b>		
<b>Statins (%)</b>	<b>100.0</b>	<b>100.0</b>
<b>simvastatin 40 mg</b>	<b>81</b>	<b>86</b>
<b>atorvastatin 20</b>	<b>19</b>	<b>14</b>
<b>Aspirin (%)</b>	<b>81</b>	<b>73</b>
<b>ACE inhibitors (%)</b>	<b>54</b>	<b>50</b>

# Effect of Aronia flavonoids or placebo on lipids, lipoproteins and homocysteine levels in patients with a history of MI


	Anthocyanins (n=22)		Placebo (n=22)		
	before	after	before	after	ANOVA
TG [mg/dl]	162.7 ± 66.2	152.7 ± 55.5	131.8 ±	127.2 ± 36.5	ns
Chol [mg/dl]	198.0 ± 25.6	199.8 ± 28.2	202.2 ±	196.0 ± 42.6	ns
LDL [mg/dl]	117.3 ± 25.9	116.9 ± 27.9	116.8 ±	110.0 ± 32.4	ns
HDL [mg/dl]	42.2 ± 9.56	43.4 ± 9.7	45.6 ± 9.2	46.4 ± 9.57	ns
Lp(a) [mg/dl]	27.3 ± 33.6	28.2 ± 37.0	25.2 ± 36.4	25.3 ± 36.3	ns
Homocysteine [μmol/l]	17.2 ± 7.3	17.1 ± 8.2	16.0 ± 7.0	16.2 ± 5.9	ns

# The effect of Aronia flavonoids on plasma total F2-isoprostanes level






# The effect of Aronia flavonoids on plasma OX-LDL level




# The effect of Aronia flavonoids on systolic blood pressure

[mmHg]





# The effect of Aronia flavonoids on diastolic blood pressure







# The effect of Aronia flavonoids or placebo on plasma ACE activity



# The effect of Aronia flavonoids on plasma IL-6 level




# The effect of Aronia flavonoids on plasma hs-CRP level






# The effect of Aronia flavonoids on plasma adiponectin level


[ $\mu\text{g/ml}$ ]



# The effect of Aronia flavonoids on plasma MCP-1 level




# Role of EPC in reendothelisation and neovascularisation





# Regulation of EPCs following the natural history of atherosclerosis




G. P. Fadini et al., *Atherosclerosis* 194 (2007) 46-54.

# Endothelial progenitor cells and atherosclerosis


- EPCs are a circulating bone marrow-derived cell population that express surface CD34, CD133 and vascular endothelial growth factor receptor 2 (VEGFR-2).
- EPCs are incorporated into the sites of endothelial denudation and provide an endogenous repair mechanism to endothelial injury.
- EPCs from subject with CVD showed in vitro accelerate senescence and reduction in telomerase activity. This effect was partially through increase of oxidative stress and inhibiting eNOS.

# Effect of *Aronia melanocarpa* polyphenols on telomerase activity in EPC







# Effect of chokeberry extract on telomerase activity in vivo in patients with CVD



# Cells incubated with 50ug of Aronia extract




# Cells incubated with oxLDL





# Cells incubated with Aronia extract and oxLDL



# Conclusions

- These results confirm the potential usefulness of natural antioxidants in the treatment of atherosclerosis, also through their effect on EPC senescence inhibition.
- Funding. This work was supported by non-restricted grants from Polish Society for Atherosclerosis Research and from Agropharm

# Conclusion

- In view of the fact that chokeberry flavonoids reduce the severity of inflammation, regardless of statins, they can be used clinically for secondary prevention of ischaemic heart disease.
- Funding. This work was supported by non-restricted grants from Polish Society for Atherosclerosis Research and from Agropharm